Soligenix

Soligenix Capital Intensity

The Capital Intensity Ratio of Soligenix (SNGX) as of Oct 16, 2026 is 7,511.44 %. In the previous year, Capital Intensity Ratio was 1,167.24 % — a change of 543.52% (higher).

Capital Intensity

7,511.44 %

YoY

543.52%

Last updated:

Capital Intensity Ratio of Soligenix is 2024 7,511.44 % . Capital Intensity Ratio of Soligenix was 2023 1,167.24 % . It decreases by 543.52% higher compared to the previous year.

The Soligenix Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2017
175.80 USD
Jan 1, 2018
200.19 USD
Jan 1, 2019
241.80 USD
Jan 1, 2020
1,030.35 USD
Jan 1, 2021
80,567.08 USD
Jan 1, 2022
5,711.89 USD
Jan 1, 2023
1,167.24 USD
Jan 1, 2024
7,511.44 USD
The Soligenix Capital Intensity history
YEARCapital IntensityYoY
7,511.44 %+543.52%
1,167.24 %-79.56%
5,711.89 %-92.91%
80,567.08 %+7,719.39%
1,030.35 %+326.12%
241.80 %+20.79%
200.19 %+13.87%
175.80 %+78.92%
98.26 %+16.63%
84.25 %-14.67%
98.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

Capital Intensity Ratio of Soligenix is 7,511.44 % in 2024.

Capital Intensity Ratio of Soligenix changed from 1,167.24 % to 7,511.44 %, representing a 543.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio Soligenix since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's Soligenix with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Soligenix

All Key Metrics — Soligenix